Dopamine (DA) induced irreversible proteasome inhibition via DA derived quinones

References

• Lotharius J, Brundin P. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat Rev Neurosci 2002; 3: 932–942
   PubMed Web of Science ®Google Scholar
• Bisaglia M, Mammi S, Bubacco L. Kinetic and structural analysis of the early oxidation products of dopamine: analysis of the interactions with alpha-synuclein. J Biol Chem 2007; 282: 15597–15605
   PubMedGoogle Scholar
• Graham DG, Tiffany SM, Bell WR, Jr, Gutknecht WF. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol 1978; 14: 644–653
   PubMed Web of Science ®Google Scholar
• Kuhn DM, Arthur R, Jr. Dopamine inactivates tryptophan hydroxylase and forms a redox-cycling quinoprotein: possible endogenous toxin to serotonin neurons. J Neurosci 1998; 18: 7111–7117
   PubMed Web of Science ®Google Scholar
• Xu Y, Stokes AH, Roskoski R, Jr, Vrana KE. Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase. J Neurosci Res 1998; 54: 691–697
   PubMed Web of Science ®Google Scholar
• Izumi Y, Sawada H, Yamamoto N, Kume T, Katsuki H, Shimohama S, Akaike A. Iron accelerates the conversion of dopamine-oxidized intermediates into melanin and provides protection in SH-SY5Y cells. J Neurosci Res 2005; 82: 126–137
   PubMed Web of Science ®Google Scholar
• Asanuma M, Miyazaki I. Nonsteroidal anti-inflammatory drugs in Parkinson's disease: possible involvement of quinone formation. Expert Rev Neurother 2006; 6: 1313–1325
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Kim J, Kobayashi N, Han S, Nakamura C, Ikebukuro K, Sode K. Pyrroloquinoline quinone (PQQ) prevents fibril formation of alpha-synuclein. Biochem Biophys Res Commun 2006; 349: 1139–1144
   PubMed Web of Science ®Google Scholar
• Berke SJ, Paulson HL. Protein aggregation and the ubiquitin proteasome pathway: gaining the UPPer hand on neurodegeneration. Curr Opin Genet Dev 2003; 13: 253–261
   PubMed Web of Science ®Google Scholar
• McNaught KS, Mytilineou C, Jnobaptiste R, Yabut J, Shashidharan P, Jennert P, Olanow CW. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J Neurochem 2002; 81: 301–306
   Google Scholar
• McNaught KS, Olanow CW, Halliwell B, Isacson O, Jenner P. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev Neurosci 2001; 2: 589–594
   PubMed Web of Science ®Google Scholar
• Benbunan BR, Korczyn AD, Giladi N. Parkin mutation associated parkinsonism and cognitive decline, comparison to early onset Parkinson's disease. J Neural Transm 2004; 111: 47–57
   Google Scholar
• Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, Harta G, Brownstein MJ, Jonnalagada S, Chernova T, Dehejia A, Lavedan C, Gasser T, Steinbach PJ, Wilkinson KD, Polymeropoulos MH. The ubiquitin pathway in Parkinson's disease. Nature 1998; 395: 451–452
   PubMed Web of Science ®Google Scholar
• Farrer M, Chan P, Chen R, Tan L, Lincoln S, Hernandez D, Forno L, Gwinn-Hardy K, Petrucelli L, Hussey J, Singleton A, Tanner C, Hardy J, Langston JW. Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol 2001; 50: 293–300
   PubMed Web of Science ®Google Scholar
• Zafar KS, Siegel D, Ross D. A potential role for cyclized quinones derived from dopamine, DOPA, and 3,4-dihydroxyphenylacetic acid in proteasomal inhibition. Mol Pharmacol 2006; 70: 1079–1086
   Google Scholar
• Bazzini E, Samuele A, Granelli M, Levandis G, Armentero MT, Nappi G, Blandini F. Proteasomal inhibition and apoptosis regulatory changes in human isolated lymphocytes: the synergistic role of dopamine. J Cell Biochem 2008; 103: 877–885
   PubMedGoogle Scholar
• Yoshimoto Y, Nakaso K, Nakashima K. L-dopa and dopamine enhance the formation of aggregates under proteasome inhibition in PC12 cells. FEBS Lett 2005; 579: 1197–1202
   PubMedGoogle Scholar
• Keller JN, Huang FF, Dimayuga ER, Maragos WF. Dopamine induces proteasome inhibition in neural PC12 cell line. Free Radic Biol Med 2000; 29: 1037–1042
   PubMed Web of Science ®Google Scholar
• Zhou Z, Kerk S, Meng Lim T. Endogenous dopamine (DA) renders dopaminergic cells vulnerable to challenge of proteasome inhibitor MG132. Free Radic Res 2008; 42: 456–466
   PubMed Web of Science ®Google Scholar
• Mytilineou C, McNaught KS, Shashidharan P, Yabut J, Baptiste RJ, Parnandi A, Olanow CW. Inhibition of proteasome activity sensitizes dopamine neurons to protein alterations and oxidative stress. J Neural Transm 2004; 111: 1237–1251
   PubMedGoogle Scholar
• Choi HK, Won LA, Kontur PJ, Hammond DN, Fox AP, Wainer BH, Hoffmann PC, Heller A. Immortalization of embryonic mesencephalic dopaminergic neurons by somatic cell fusion. Brain Res 1991; 552: 67–76
   PubMed Web of Science ®Google Scholar
• Dick LR, Cruikshank AA, Destree AT, Grenier L, McCormack TA, Melandri FD, Nunes SL, Palombella VJ, Parent LA, Plamondon L, Stein RL. Mechanistic studies on the inactivation of the proteasome by lactacystin in cultured cells. J Biol Chem 1997; 272: 182–188
   PubMed Web of Science ®Google Scholar
• Rao S, Porter DC, Chen X, Herliczek T, Lowe M, Keyomarsi K. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci USA 1999; 96: 7797–7802
   PubMed Web of Science ®Google Scholar
• Braun HA, Umbreen S, Groll M, Kuckelkorn U, Mlynarczuk I, Wigand ME, Drung I, Kloetzel PM, Schmidt B. Tripeptide mimetics inhibit the 20 S proteasome by covalent bonding to the active threonines. J Biol Chem 2005; 280: 28394–28401
   Google Scholar
• Zhou ZD, Lim TM. Roles of glutathione (GSH) in dopamine (DA) oxidation studied by improved tandem HPLC plus ESI-MS. Neurochem Res 2009; 34: 316–326
   Google Scholar
• McNaught KS, Belizaire R, Jenner P, Olanow CW, Isacson O. Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. Neurosci Lett 2002; 326: 155–158
   PubMed Web of Science ®Google Scholar
• Klegeris A, Korkina LG, Greenfield SA. Autoxidation of dopamine: a comparison of luminescent and spectrophotometric detection in basic solutions. Free Radic Biol Med 1995; 18: 215–222
   Google Scholar
• Jenner P, Dexter DT, Sian J, Schapira AH, Marsden CD. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol 1992;32(Suppl):S82–S87.
   PubMedGoogle Scholar
• Spencer JP, Jenner P, Halliwell B. Superoxide-dependent depletion of reduced glutathione by L-DOPA and dopamine. Relevance to Parkinson's disease. Neuroreport 1995; 6: 1480–1484
   PubMed Web of Science ®Google Scholar
• Spencer JP, Jenner P, Daniel SE, Lees AJ, Marsden DC, Halliwell B. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. J Neurochem 1998; 71: 2112–2122
   PubMed Web of Science ®Google Scholar
• Piga R, Saito Y, Yoshida Y, Niki E. Cytotoxic effects of various stressors on PC12 cells: involvement of oxidative stress and effect of antioxidants. Neurotoxicology 2007; 28: 67–75
   PubMed Web of Science ®Google Scholar
• Banaclocha MM. Therapeutic potential of N-acetylcysteine in age-related mitochondrial neurodegenerative diseases. Med Hypotheses 2001; 56: 472–477
   PubMed Web of Science ®Google Scholar
• Munoz AM, Rey P, Soto-Otero R, Guerra MJ, Labandeira-Garcia JL. Systemic administration of N-acetylcysteine protects dopaminergic neurons against 6-hydroxydopamine-induced degeneration. J Neurosci Res 2004; 76: 551–562
   PubMed Web of Science ®Google Scholar
• Martinez Banaclocha M. N-acetylcysteine elicited increase in complex I activity in synaptic mitochondria from aged mice: implications for treatment of Parkinson's disease. Brain Res 2000; 859: 173–175
   Google Scholar
• Zhou ZD, Kerk SY, Xiong GG, Lim TM. Dopamine auto-oxidation aggravates non-apoptotic cell death induced by overexpression of human A53T mutant alpha-synuclein in dopaminergic PC12 cells. J Neurochem 2009; 108: 601–610
   Google Scholar
• Salazar J, Mena N, Nunez MT. Iron dyshomeostasis in Parkinson's disease. J Neural Transm Suppl 2006;205–213.
   Google Scholar
• Bharath S, Hsu M, Kaur D, Rajagopalan S, Andersen JK. Glutathione, iron and Parkinson's disease. Biochem Pharmacol 2002; 64: 1037–1048
   PubMed Web of Science ®Google Scholar